W
William Small
Researcher at Loyola University Chicago
Publications - 423
Citations - 15241
William Small is an academic researcher from Loyola University Chicago. The author has contributed to research in topics: Radiation therapy & Brachytherapy. The author has an hindex of 56, co-authored 396 publications receiving 12744 citations. Previous affiliations of William Small include University of Hong Kong & University of Chicago.
Papers
More filters
Journal ArticleDOI
The role of vaginal cuff brachytherapy in endometrial cancer.
TL;DR: VBT decreases the risk of recurrence with minimal toxicity in the adjuvant treatment of endometrial cancer and should be discussed in a multi-disciplinary setting with detailed counseling of the risks and benefits with the patient so that she ultimately makes an informed decision regarding her adjUvant therapy.
Journal ArticleDOI
A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study
Marcus E. Randall,Virginia L. Filiaci,D. S. McMeekin,Catheryn M. Yashar,Robert S. Mannel,Ritu Salani,P. DiSilvestro,James J. Burke,Thomas J. Rutherford,Nicola M. Spirtos,J. Cho,Jae Weon Kim,Penny R. Anderson,Wendy R. Brewster,William Small,Michael E. Carney,Carol Aghajanian,David Miller +17 more
Journal ArticleDOI
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
David K. Gaffney,Kathryn Winter,Adam P. Dicker,Brigitte Miller,Patricia J. Eifel,J. Ryu,Vilija N. Avizonis,Mitch Fromm,William Small,Kathryn M. Greven +9 more
TL;DR: At 2 years, the estimated disease-free survival and overall survival rate for patients with advanced cervical cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69% and 83%, respectively.
Journal ArticleDOI
A Phase III Randomized Trial Comparing Patient-Reported Toxicity and Quality of Life (QOL) During Pelvic Intensity Modulated Radiation Therapy as Compared to Conventional Radiation Therapy.
Ann H. Klopp,A.R. Yeung,S. Deshmukh,Karen M. Gil,Lari Wenzel,Shannon N. Westin,Kent A Gifford,David K. Gaffney,William Small,Spencer Thompson,Desiree E. Doncals,Guilherme Cantuaria,Brian Yaremko,Amy T.Y. Chang,Vijayananda Kundapur,D.S. Mohan,Michael L. Haas,Yong Bae Kim,C.L. Ferguson,D. Watkins Bruner +19 more
Journal ArticleDOI
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours
Alexandra Leary,Michael A. Quinn,Keiichi Fujiwara,Robert L. Coleman,Elise C. Kohn,T. Sugiyama,R.M. Glasspool,I.L. Ray-Coquard,Nicoletta Colombo,Monica Bacon,Alain G. Zeimet,Anneke M. Westermann,E. Gomez-Garcia,D. Provencher,Stephen Welch,William Small,David Millan,Aikou Okamoto,Gavin Stuart,Kazunori Ochiai +19 more
TL;DR: This manuscript reports the consensus statements on designing clinical trials in rare ovarian tumours reached at the fifth Ovarian Cancer Consensus Conference (OCCC) held in Tokyo, November 2015.